ZAI LAB LIMITED Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
ZAI LAB LIMITED (ZLAB) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $3.54 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-02-26
- ZAI LAB LIMITED share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $3.54, a 109.47% increase from fiscal 2024.
- ZAI LAB LIMITED share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $1.69, a 49.70% decline from fiscal 2023.
- ZAI LAB LIMITED share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $3.36, a 23.11% decline from fiscal 2022.
- ZAI LAB LIMITED share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $4.37, a 96.53% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|
| 2025-12-31 | $3.54 10-K · filed 2026-02-26 | |
| 2024-12-31 | $1.69 10-K · filed 2025-02-27 | |
| 2023-12-31 | $3.36 10-K · filed 2024-02-27 | |
| 2022-12-31 | $4.37 10-K · filed 2023-03-01 | |
| 2021-12-31 | $126.02 10-K · filed 2022-03-01 | |
| 2020-12-31 | $63.98 10-K · filed 2021-03-01 | |
| 2020-06-30 | $52.80 6-K · filed 2020-09-11 | |
| 2019-12-31 | $32.22 10-K · filed 2021-03-01 | |
| 2019-06-30 | $28.40 6-K · filed 2020-09-11 | |
| 2018-12-31 | $21.15 10-K · filed 2021-03-01 | |
| 2017-12-31 | $8.76 20-F · filed 2020-04-29 | |
| 2016-12-31 | $1.53 20-F · filed 2019-03-29 | |
| 2015-12-31 | $0.60 20-F · filed 2018-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |